## CITATION REPORT List of articles citing

A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases

DOI: 10.1007/s10120-012-0204-z Gastric Cancer, 2013, 16, 411-9.

**Source:** https://exaly.com/paper-pdf/54904151/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
35	Multimodale Therapie beim lokal begrenzten Magenkarzinom. <i>Im Focus Onkologie</i> , <b>2014</b> , 17, 59-66	O	
34	Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats. <i>Xenobiotica</i> , <b>2014</b> , 44, 804-18	2	7
33	Clinical significance of chemotherapy for geriatric patients with advanced or recurrent gastric cancer. <i>Molecular and Clinical Oncology</i> , <b>2015</b> , 3, 83-88	1.6	5
32	Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer Chemotherapy and Pharmacology, <b>2015</b> , 75, 941-7	3.5	22
31	Chemotherapy in Elderly Patients with Gastric Cancer. <i>Journal of Cancer</i> , <b>2016</b> , 7, 88-94	4.5	28
30	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2016</b> , 27, v38-v49	10.3	796
29	A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. <i>Gastric Cancer</i> , <b>2016</b> , 19, 245-54	7.6	5
28	Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. <i>Oncologist</i> , <b>2017</b> , 22, 293-303	5.7	5
27	Feasibility of Modified FOLFOX in Elderly Patients Aged <b>B</b> 0 Years with Metastatic Gastric Cancer or Colorectal Cancer. <i>Oncology</i> , <b>2017</b> , 93, 115-121	3.6	6
26	Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 1117-1124	3.6	7
25	Management of gastric cancer in older adults. <i>Journal of Geriatric Oncology</i> , <b>2017</b> , 8, 403-406	3.6	5
24	Safety and efficacy of dose-dense chemotherapy with TCF regimen in elderly patients with locally advanced or metastatic gastric cancer. <i>Tumori</i> , <b>2017</b> , 103, 93-100	1.7	2
23	Different Chemosensitization Approaches in Gastric Cancer. <b>2018</b> , 267-319		1
22	Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis. <i>Journal of Geriatric Oncology</i> , <b>2018</b> , 9, 254-264	3.6	10
21	Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 375-381	4.4	8
20	. Zeitschrift Fur Gastroenterologie, <b>2019</b> , 57, 336-418	1.6	10
19	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 591-597	3.6	4

18	Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study. <i>EBioMedicine</i> , <b>2020</b> , 61, 103023	8.8	6
17	Challenges in the treatment of gastric cancer in the older patient. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 85, 101980	14.4	27
16	Aortic dissection after ramucirumab infusion. European Journal of Hospital Pharmacy, 2020, 27, 117-120	1.6	3
15	Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. <i>Journal of Chemotherapy</i> , <b>2021</b> , 33, 51-55	2.3	3
14	Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment. <i>Anti-Cancer Drugs</i> , <b>2021</b> , 33,	2.4	0
13	Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 100, 102289	14.4	1
12	Chemotherapy and resection for gastric cancer with synchronous liver metastases. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 2097-103	5.6	30
11	Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 4911-8	5.6	7
10	Gastric Cancer in the Elderly. <b>2017</b> , 1-26		
9	Magenkarzinom beim alten und geriatrischen Patienten. <b>2017</b> , 1-8		
8	Magenkarzinom beim alten und geriatrischen Patienten. <b>2018</b> , 325-332		
7	CHEMOTHERAPY IN ELDERLY PATIENTS WITH STOMACH CANCER. <i>Malignant Tumours</i> , <b>2018</b> , 8, 64-75	0.3	2
6	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. <b>2019</b> , 1-28		
5			
	Gastric Cancer in the Elderly. <b>2020</b> , 931-956		
4	Gastric Cancer in the Elderly. 2020, 931-956  Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. 2020, 731-	757	О
		757 7.6	0
4	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. <b>2020</b> , 731- Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS) <i>Gastric</i>		